-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $57

Benzinga·03/10/2026 14:14:36
Listen to the news
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $53 to $57.